Pomerantz Law Firm Alerts Investors of Class Action Against Actinium Pharmaceuticals: Key Details and Next Steps

Investor Alert: Class Action Lawsuit Filed Against Actinium Pharmaceuticals

Pomerantz LLP, a prominent law firm specializing in securities class actions, has officially announced the initiation of a class action lawsuit against Actinium Pharmaceuticals, Inc. The firm is reaching out to investors who have experienced financial losses while investing in Actinium's securities, particularly during a specified class period. The lawsuit highlights allegations of potential securities fraud and misconduct by certain officers and directors of the company, raising concerns about the integrity of the company’s business practices.

Background Information

On August 5, 2024, Actinium Pharmaceuticals made a concerning announcement regarding its planned Biologics License Application for its product, Iomab-B, which is aimed at patients with active relapsed or refractory acute myeloid leukemia (r/r AML). In a press release, the company revealed that the U.S. Food and Drug Administration (FDA) deemed their Phase 3 SIERRA trial inadequate to support the BLA filing despite initial indications of statistical significance.

This unexpected announcement had a significant impact on the market, causing Actinium’s stock price to plummet by $3.69 per share, nearly 60%, closing at $2.48 the same day. Such drastic changes can potentially spell disaster for investors who may have acted on misleading information.

What This Means for Investors

Investors who acquired Actinium securities within the relevant class period are encouraged to take immediate action, especially if they have suffered losses. According to Pomerantz LLP, the deadline to request the appointment as Lead Plaintiff in this class action case is May 26, 2025. Interested investors should reach out to Danielle Peyton at the firm either by phone or email—providing their contact information and the number of shares purchased could assist with their claim.

The class action lawsuit aims to recover damages for investors who may have suffered losses due to the company’s alleged unlawful practices. Pomerantz LLP emphasizes its role in advocating for investor rights and ensuring that those affected by corporate misconduct are compensated fairly.

How to Join the Lawsuit

Investors looking to join the class action against Actinium Pharmaceuticals can obtain a copy of the complaint filed by visiting Pomerantz Law Firm’s official website. It's vital for harmed investors to engage in this process promptly to exercise their legal rights and ensure their voices are heard. The firm’s long history in combating securities fraud and corporate misconduct enhances its credibility and effectiveness in these instances.

Pomerantz LLP operates from various cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. They are recognized as leaders in the securities class action field and have a track record of recovering significant damage awards for investors.

In summary, if you are one of the investors affected by Actinium Pharmaceuticals' recent developments, now is the time to consult with legal experts and consider your options. Keeping track of deadlines and properly filing your claims can be crucial in the pursuit of justice and financial recovery.

Contact Information

For more information or to get involved, contact Danielle Peyton at Pomerantz LLP through their email or phone for guidance. Remember to include your details as they can assist in determining your eligibility within the context of this important lawsuit.